Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés
Lara
L
González
Marta
M
Polo
Isabel
I
Enguita
Ana B
AB
Vanaclocha
Francisco
F
Ortiz-Romero
Pablo L
PL
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008060:Lipodystrophy / Q000139:chemically induced* / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy*; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy*; D013848:Thigh; D055815:Young Adult
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins